1. Scrip
  2. >>Drug Pricing

Stock Watch: Gaming The US Health Care System

Pharmacies Should Be Held To Account For Role In Drug Price Inflation

 
• By Andy Smith

The pharmaceutical sector is often unfairly demonized in the drug pricing debate. Other participants exploit the complex US health care system almost with impunity.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Most developed market taxation systems distinguish between tax avoidance and tax evasion – only the latter is illegal. Avoidance involves gaming a complex taxation system replete with regulations and loopholes, which allows some individuals and corporations to pay less tax. US health care is also a complex system where gaming can result in its exploitation.

Complex systems, like the weather, are comprised of many components and forces that interact with each other and make accurate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.